AI may help predict tumor sensitivity to systemic cancer therapies
Generally, researchers have studied how cancer cells spread by looking at the proteins on their surface membranes. Some of these proteins may serve as receptors that engage with other cells, allowing cancerous cells to attach and move into tissues.
But proteins on living cells are also coated with a wide variety of sugarlike carbohydrate molecules called glycans. These glycans modify how proteins -- and therefore the cells -- interact with their environment. While DNA dictates the protein's structure, glycans and carbohydrates are made and metabolized by the protein's own machinery. That makes studying these molecules even more challenging.
Lebrilla's laboratory at UC Davis has been studying glycans, glycoproteins and the roles they play in the body for many years, developing new techniques to analyze and characterize them. How glycans modify proteins
Metastatic cholangiocarcinoma cells had high levels of the glycan mannose on surface proteins, Lebrilla's team discovered. These cancer cells lacked the gene for an enzyme that breaks down mannose. The presence of mannose was associated with cancer cells being able to spread out on a dish and migrate through pores in a membrane, simulating squeezing through the wall of a blood vessel into surrounding tissue.
What is interesting here is that it's a new way to look at cancer metastasis. Instead of looking at proteins, we've looked at how protein modifications are affecting the metastatic behavior of cancer cells." Professor Carlito Lebrilla, UC Davis Department of Chemistry
If modified glycans are a characteristic of metastatic cancers, that could present a new way to diagnose cancer and perhaps predict which cancers are likely to become invasive. The glycans and the metabolic pathways that make them could also be targets for new drugs. Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology